Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Invest. 2008 Jul;118(7):2372-9. doi: 10.1172/JCI33452.

Molecular pathogenesis of pulmonary arterial hypertension.

Author information

1
Department of Pediatrics, Stanford University School of Medicine, Stanford, California 94305-5162, USA. marlener@stanford.edu

Abstract

Recent investigations have suggested that it might be possible to reverse the pathology of pulmonary arterial hypertension (PAH), a disorder that can be rapidly progressive and fatal despite current treatments including i.v. prostacyclin. This review will address the cellular and molecular processes implicated in clinical, genetic, and experimental studies as underlying the pulmonary vascular abnormalities associated with PAH. Emerging treatments are aimed at inducing apoptosis of abnormal vascular cells that obstruct blood flow and at promoting regeneration of "lost" distal vasculature.

PMID:
18596905
PMCID:
PMC2439479
DOI:
10.1172/JCI33452
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for American Society for Clinical Investigation Icon for PubMed Central
    Loading ...
    Support Center